aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАН10.52727/2078-256X-2021-17-2-83-93ateroskleroz-439Research ArticleОБЗОРЫREVIEWSГиперхолестеринемия в молодом возрастеHypercholesterolemia at a young agehttps://orcid.org/0000-0003-4892-0861СпиридоновА. Н.SpiridonovA. N.

 врач-ординатор по специальности «кардиология»

 630089, г. Новосибирск, ул. Бориса Богаткова 175/1 

 630089, Novosibirsk, Boris Bogatkov str., 175/1 

Spiridonov.al16@yandex.ruhttps://orcid.org/0000-0002-4936-8362РагиноЮ. И.RaginoYu. I.

 д-р мед. наук, проф., чл.-корр. РАН, руководитель 

 630089, г. Новосибирск, ул. Бориса Богаткова 175/1 

 630089, Novosibirsk, Boris Bogatkov str., 175/1 

ragino@mail.ruНИИ терапии и профилактической медицины – филиал ФГБНУ ФИЦ Институт цитологии и генетики СО РАНResearch Institute of Internal and Preventive Medicine – Branch of Federal Research Center Institute of Cytology and Genetics of SB RAS2021100820211728393Copyright © Спиридонов А.Н., Рагино Ю.И., 20212021Спиридонов А.Н., Рагино Ю.И.Spiridonov A.N., Ragino Y.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/439

 В настоящем обзоре проведен анализ данных мировой литературы, посвященных проблеме семейной гиперхолестеринемии в молодом возрасте; обсуждается ее  распространенность на территории как Российской Федерации, так и всего мира. Проанализирована проблема увеличения риска сердечно-сосудистых событий в  зависимости от возраста. Представлены результаты исследований, в которых изучены вопросы эффективности существующих шкал оценки риска в молодом возрасте, а также критерии фенотипической диагностики, включая DLCNC, Simon Broome, MEDPED, японские критерии. Дан  обзор исследований, направленных на изучение  эффективности влияния медикаментозной и  немедикаментозной терапии на уровень холестерина. Анонсированы инновационные методы коррекции  гиперхолестеринемии. Использованы сведения на основе данных баз данных PubMed, Google Scholar. 

 In the present review the analysis of the world literature devoted to the problem of familial hypercholesterolemia at a young age was carried out. Its prevalence both on the territory of the Russian Federation and on the territory of the whole world is discussed. The problem of increased risk of age-dependent cardiovascular events is analyzed. The results of research examining the effectiveness of existing risk assessment scales at a young age, as well as the phenotypic diagnostic criteria, including DLCNC, Simon Broome, MEDPED and Japanese criteria are presented. An overview of studies aimed at investigation of the drug and non-drug therapy positive effect on cholesterol levels is given. Innovative methods of hypercholesterolemia correction were announced. The  information on the topic from publications based on PubMed and Google Scholar data were used.

семейная гиперхолестеринемиямолодой возрастишемическая болезнь сердцаFamilial hypercholesterolemiayoung agecoronary artery diseaseReferencesRidker P.M., Cook N.R. Cholesterol evaluation in young adults: absence of clinical trial evidence is not a reason to delay screening. Ann. Intern. Med., 2017; 166 (12): 901–902. doi: 10.7326/M17-0855Ridker P.M., Cook N.R. Cholesterol evaluation in young adults: absence of clinical trial evidence is not a reason to delay screening. Ann. Intern. Med., 2017; 166 (12): 901–902. doi: 10.7326/M17-0855Moradi A., Maleki M., Ghemmaghami Z., Khajali Z., Noohi F., Moghadam M.H., Malakootian M. Mutational spectrum of LDLR and PCSK9 genes identified in Iranian patients with premature coronary artery disease and familial hypercholesterolemia. Front. Genet., 2021; 12: 64–76. doi: 10.3389/fgene.2021.625959Moradi A., Maleki M., Ghemmaghami Z., Khajali Z., Noohi F., Moghadam M.H., Malakootian M. Mutational spectrum of LDLR and PCSK9 genes identified in Iranian patients with premature coronary artery disease and familial hypercholesterolemia. Front. Genet., 2021; 12: 64–76. doi: 10.3389/fgene.2021.625959Doi T., Hori M., Harada-Shiba M., Kataoka Y., Onozuka D., Nishimura K., Yasuda S. Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia. J. Am. Heart. Assoc., 2021; 10: 1–11. e018263. doi: 10.1161/jaha.120.018263Doi T., Hori M., Harada-Shiba M., Kataoka Y., Onozuka D., Nishimura K., Yasuda S. Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia. J. Am. Heart. Assoc., 2021; 10: 1–11. e018263. doi: 10.1161/jaha.120.018263Hori M., Takahashi A., Son C., Ogura M., HaradaShiba M. The first Japanese cases of familial hypercholesterolemia due to a known pathogenic APOB gene variant, c. 10580 G> A: p.(Arg3527Gln). J. Clin. Lipidol., 2020; 14 (4): 482–486. doi: 10.1016/j.jacl. 2020.05.007Hori M., Takahashi A., Son C., Ogura M., HaradaShiba M. The first Japanese cases of familial hypercholesterolemia due to a known pathogenic APOB gene variant, c. 10580 G> A: p.(Arg3527Gln). J. Clin. Lipidol., 2020; 14 (4): 482–486. doi: 10.1016/j.jacl. 2020.05.007Смолина М.О., Бенимецкая К.С., Рагино Ю.И., Воевода М.И. PCSK9: новые победы и горизонты. Атеросклероз, 2018; 14 (3): 70–77. doi: 10.15372/ater20180311Smolina M.O., Benimetskaya K.S., Ragino Yu.I., Voevoda M.I. PCSK9: new victories and horizons. Aterosklero, 2018; 14 (3): 70–77. (In Russ.) doi: 10.15372/ater20180311El Khoury P., Elbitar S., Ghaleb Y., Abou Khalil Y., Varret M., Boileau C., Abifadel M. PCSK9 mutations in familial hypercholesterolemia: from a groundbreaking discovery to anti-PCSK9 therapies. Curr. Atheroscler. Rep., 2017; 19 (12): 1–13. doi: 10.1007/s11883-017-0684-8El Khoury P., Elbitar S., Ghaleb Y., Abou Khalil Y., Varret M., Boileau C., Abifadel M. PCSK9 mutations in familial hypercholesterolemia: from a groundbreaking discovery to anti-PCSK9 therapies. Curr. Atheroscler. Rep., 2017; 19 (12): 1–13. doi: 10.1007/s11883-017-0684-8D’Erasmo L., di Costanzo A., Arca M. Autosomal recessive hypercholesterolemia: update for 2020. Curr. Opin. Lipidol., 2020; 31 (2): 56–61. doi: 10.1097/mol.0000000000000664D’Erasmo L., di Costanzo A., Arca M. Autosomal recessive hypercholesterolemia: update for 2020. Curr. Opin. Lipidol., 2020; 31 (2): 56–61. doi: 10.1097/mol.0000000000000664Bagnasco M.S. Familial Hypercholesterolemia. Dyslipidemia: IntechOpen, 2021. doi: 10.5772/intechopen.96031Bagnasco M.S. Familial Hypercholesterolemia. Dyslipidemia: IntechOpen, 2021. doi: 10.5772/intechopen.96031Soutar A.K., Naoumova R.P. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc., Med., 2007; 4 (4): 214–225. doi: 10.1038/ncpcardio0836Soutar A.K., Naoumova R.P. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc., Med., 2007; 4 (4): 214–225. doi: 10.1038/ncpcardio0836Yamamoto T., Davis C.G., Brown M.S., Schneider W.J., Casey M.L., Goldstein J.L., Russell D.W. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell, 1984; 39 (1): 27–38. doi:10.1016/0092-8674(84)90188-0Yamamoto T., Davis C.G., Brown M.S., Schneider W.J., Casey M.L., Goldstein J.L., Russell D.W. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell, 1984; 39 (1): 27–38. doi:10.1016/0092-8674(84)90188-0Здорикова М.А., Казакова Т.Е., Димов И.Д., Сесорова И.С. Молекулярные механизмы транспорта липидов из эндоплазматического ретикулюма в комплекс Гольджи в энтероците кишечной ворсинки. Междунар. журн. прикл. и фундамент. исследований, 2019; 11: 30–34. https://www.elibrary.ru/item.asp?id=41561757Zdorikova M.A., Kazakova T.E., Dimov I.D., Sesorova I.S. Molecular mechanisms of lipid transport from the endoplasmic reticulum to the Golgi complex in the intestinal villus enterocyte. Mezhdunarodnyi zhurnal prikladnykh i fundamental’nykh issledovanii, 2019. 11: 30–34. (In Russ.) https://www.elibrary.ru/item.asp?id=41561757Myant N.B. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis, 1993; 104 (1-2): 1–18. doi: 10.1016/0021-9150(93)90171-PMyant N.B. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis, 1993; 104 (1-2): 1–18. doi: 10.1016/0021-9150(93)90171-PЧаулин А.М., Александров А.Г., Александрова О.С., Дупляков Д.В. Роль пропротеин-конвертазы субтилизин/кексин типа 9 (pcsk9) в патофизиологии атеросклероза. Медицина в Кузбассе, 2019; 18 (4): 5–15. https://cyberleninka.ru/article/n/rol-proprotein-konvertazy-subtilizin-keksintipa-9-pcsk9-v-patofiziologii-ateroskleroza/viewerChaulin A.M., Aleksandrov A.G., Aleksandrova O.S., Duplyakov D.V. The role of proprotein convertase subtilisin / kexin type 9 (pcsk9) in the pathophysiology of atherosclerosis. Meditsina v Kuzbasse, 2019; 18: 5–15. (In Russ.) https://cyberleninka.ru/article/n/rol-proprotein-konvertazy-subtilizin-keksintipa-9-pcsk9-v-patofiziologii-ateroskleroza/viewerDing Z., Pothineni N.V.K., Goel A., Lüscher T.F., Mehta J.L. PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1. Cardiovasc. Res., 2020; 116 (5): 908–915. doi: 10.1093/cvr/cvz313Ding Z., Pothineni N.V.K., Goel A., Lüscher T.F., Mehta J.L. PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1. Cardiovasc. Res., 2020; 116 (5): 908–915. doi: 10.1093/cvr/cvz313Nordestgaard B.G., Chapman M.J., Ray K., Borén J., Andreotti F., Watts G.F., Tybjærg-Hansen A. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur. Heart. J., 2010; 31 (23): 2844–2853 doi: 10.1093/eurheartj/ehq386Nordestgaard B.G., Chapman M.J., Ray K., Borén J., Andreotti F., Watts G.F., Tybjærg-Hansen A. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur. Heart. J., 2010; 31 (23): 2844–2853 doi: 10.1093/eurheartj/ehq386Bucholz E.M., Rodday A.M., Kolor K., Khoury M.J., de Ferranti S.D. Prevalence and predictors of cholesterol screening, awareness, and statin treatment among US adults with familial hypercholesterolemia or other forms of severe dyslipidemia (1999–2014). Circulation, 2018; 137: 2218–2230. doi: 10.1161/circulationaha.117.032321Bucholz E.M., Rodday A.M., Kolor K., Khoury M.J., de Ferranti S.D. Prevalence and predictors of cholesterol screening, awareness, and statin treatment among US adults with familial hypercholesterolemia or other forms of severe dyslipidemia (1999–2014). Circulation, 2018; 137: 2218–2230. doi: 10.1161/circulationaha.117.032321de Ferranti S.D., Rodday A.M., Mendelson M.M., Wong J.B., Leslie L.K., Sheldrick R.C. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation, 2016; 133: 1067–1072. doi: 10.1161/circulationaha.115.018791de Ferranti S.D., Rodday A.M., Mendelson M.M., Wong J.B., Leslie L.K., Sheldrick R.C. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation, 2016; 133: 1067–1072. doi: 10.1161/circulationaha.115.018791Mortensen M.B., Kulenovic I., Klausen I.C., Falk E. Familial hypercholesterolemia among unselected contemporary patients presenting with first myocardial infarction: Prevalence, risk factor burden, and impact on age at presentation. J. Clin. Lipidol., 2016; 10 (5): 1145–1152. doi: 10.1016/j.jacl.2016.06.002Mortensen M.B., Kulenovic I., Klausen I.C., Falk E. Familial hypercholesterolemia among unselected contemporary patients presenting with first myocardial infarction: Prevalence, risk factor burden, and impact on age at presentation. J. Clin. Lipidol., 2016; 10 (5): 1145–1152. doi: 10.1016/j.jacl.2016.06.002Khera A.V., Won H.H., Peloso G.M., Lawson K.S., Bartz T.M., Deng X., van Leeuwen E.M., Natarajan P., Emdin C.A., Bick A.G., Morrison A.C., Brody J.A., Gupta N., Nomura A., Kessler T., Duga S., Bis J.C., van Duijn C.M., Cupples L.A., Psaty B., Rader D.J., Danesh J., Schunkert H., Person R., Farrall M., Watkins H., Lander E., Wilson J.G., Correa A., Boerwinkle E., Merlini P.A., Ardissino D., Saleheen D., Gabriel S., Kathiresan S. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J. A. Coll. Cardiol., 2016; 67: 2578–2589. doi: 10.1016/j.jacc.2016.03.520soKhera A.V., Won H.H., Peloso G.M., Lawson K.S., Bartz T.M., Deng X., van Leeuwen E.M., Natarajan P., Emdin C.A., Bick A.G., Morrison A.C., Brody J.A., Gupta N., Nomura A., Kessler T., Duga S., Bis J.C., van Duijn C.M., Cupples L.A., Psaty B., Rader D.J., Danesh J., Schunkert H., Person R., Farrall M., Watkins H., Lander E., Wilson J.G., Correa A., Boerwinkle E., Merlini P.A., Ardissino D., Saleheen D., Gabriel S., Kathiresan S. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J. A. Coll. Cardiol., 2016; 67: 2578–2589. doi: 10.1016/j.jacc.2016.03.520soМетельская В.А., Шальнова С.А., Деев А.Д., Перова Н.В., Гомыранова Н.В., Литинская О.А., Евстифеева С.Е., Артамонова Г.В., Гатагонова Т.М., Гринштейн Ю.И., Дупляков Д.В., Ефанов А.Ю., Жернакова Ю.В., Ильин В.А., Либис Р.А., Минаков А.В., Невзорова В.А., Недогода С.В., Романчук С.А., Ротарь О.П., Трубачева И.А., Шляхто Е.В., Бойцов С.А. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жи-телей Российской Федерации (по данным исследования ЭССЭ-РФ). Профилакт. медицина, 2016; 19 (1): 15–23. doi: 10.17116/profmed201619115-23Metel’skaya V.A., Shal’nova S.A., Deev A.D., Perova N.V., Gomyranova N.V., Litinskaya O.A., Evstifeeva S.E., Artamonova G.V., Gatagonova T.M.,Grinshtein Yu.I., Duplyakov D.V., Efanov A.Yu., Zhernakova Yu.V., Il’in V.A., Libis R.A., Minakov A.V., Nevzorova V.A., Nedogoda S.V., Romanchuk S.A., Rotar’ O.P., Trubacheva I.A., Shlyakhto E.V., Boitsov S.A. Analysis of the prevalence of indicators characterizing the atherogenicity of the lipoprotein spectrum in residents of the Russian Federation (according to the ESSE-RF study). Profilakticheskaya meditsina, 2016; 19 (1): 15–23. (In Russ.) doi: 10.17116/profmed201619115-23Ежов М.В., Сергиенко И.В., Дупляков Д.В., Абашина О.Е., Качковский М.А., Шапошник И.И., Генкель В.В., Гуревич В.С., Уразгильдеева С.А., Трегубов А.В., Коновалова Т.В., Музалевская М.В., Воевода М.И., Бажан С.С., Макаренкова К.В., Тимощенко О.В., Рагино Ю.И., Урванцева И.А., Кожокарь К.Г., Соколов А.А., Боева О.И., Болотова Е.В., Кушнарёва Ю.Б., Кузнецова Т.Ю., Корнева В.А., Богданов Д.Ю., Чичина Е.Е., Соловьев В.М., Смоленская О.Г., Галявич А.С., Сафарова М.С., Попова А.В., Малахов В.В., Аншелес А.А., Нозадзе Д.Н., Семенова Е.Е., Рожкова Т.А., Соловьева Е.Ю., Горнякова Н.Б., Карпов Ю.А., Кухарчук В.В. Результаты Российской научно-исследовательской программы по диагностике и лечению больных семейной гиперхолестеринемией. Высокая распространенность, низкая информированность, плохая приверженность. Атеросклероз и дислипидемии, 2017; 2 (27): 5–15. https://www.elibrary.ru/item.asp?id=29429039Ezhov M.V., Sergienko I.V., Duplyakov D.V., Abashina O.E., Kachkovskii M.A., Shaposhnik I.I., Genkel’ V.V., Gurevich V.S., Urazgil’deeva S.A., Tregubov A.V., Konovalova T.V., Muzalevskaya M.V., Voevoda M.I., Bazhan S.S., Makarenkova K.V., Timoshchenko O.V., Ragino Yu.I., Urvantseva I.A., Kozhokar’ K.G., Sokolov A.A., Boeva O.I., Bolotova E.V., Kushnareva Yu.B., Kuznetsova T.Yu., Korneva V.A., Bogdanov D.Yu., Chichina E.E., Solov’ev V.M., Smolenskaya O.G., Galyavich A.S., Safarova M.S., Popova A.V., Malakhov V.V., Ansheles A.A., Nozadze D.N., Semenova E.E., Rozhkova T.A., Solov’eva E.Yu., Gornyakova N.B., Karpov Yu.A., Kukharchuk V.V. Results of the Russian research program for the diagnosis and treatment of patients with familial hypercholesterolemia. High prevalence, low awareness, poor adherence. Ateroskleroz i dislipidemii, 2017; 2 (27): 5–15. (In Russ.) https://www.elibrary.ru/item.asp?id=29429039Harada-Shiba M., Ako J., Arai H., Hirayama A., Murakami Y., Nohara A., Nakamura M. Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the exploreJ study. Atherosclerosis, 2018; 277: 362–368. doi: 10.1016/j.atherosclerosis.2018.06.856Harada-Shiba M., Ako J., Arai H., Hirayama A., Murakami Y., Nohara A., Nakamura M. Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the exploreJ study. Atherosclerosis, 2018; 277: 362–368. doi: 10.1016/j.atherosclerosis.2018.06.856Watts G.F., Gidding S., Wierzbicki A.S., Toth P.P., Alonso R., Brown W.V., Kastelein J.J. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int. J. Cardiol., 2014; 171: 309–324. doi: 10.1016/j.ijcard.2013.11.025Watts G.F., Gidding S., Wierzbicki A.S., Toth P.P., Alonso R., Brown W.V., Kastelein J.J. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int. J. Cardiol., 2014; 171: 309–324. doi: 10.1016/j.ijcard.2013.11.025Kramer A.I., Trinder M., Brunham L.R. Estimating the prevalence of familial hypercholesterolemia in acute coronary syndrome: a systematic review and meta-analysis. Can. J. Cardiol., 2019; 35 (10): 1322–1331. doi: 10.1016/j.cjca.2019.06.017Kramer A.I., Trinder M., Brunham L.R. Estimating the prevalence of familial hypercholesterolemia in acute coronary syndrome: a systematic review and meta-analysis. Can. J. Cardiol., 2019; 35 (10): 1322–1331. doi: 10.1016/j.cjca.2019.06.017Myers K.D. Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data. Lancet. Digit. Health., 2019; 1 (8): 393–402. doi: 10.1016/S2589-7500(19)30150-5Myers K.D. Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data. Lancet. Digit. Health., 2019; 1 (8): 393–402. doi: 10.1016/S2589-7500(19)30150-5Neil A., Cooper J., Betteridge J., Capps N., McDowell I., Durrington P., Humphries S.E. Reductions in all-cause, cancer, and coronary mortality in statintreated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur. Heart. J., 2008; 29 (21): 2625–2633. doi: 10.1093/eurheartj/ehn422Neil A., Cooper J., Betteridge J., Capps N., McDowell I., Durrington P., Humphries S.E. Reductions in all-cause, cancer, and coronary mortality in statintreated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur. Heart. J., 2008; 29 (21): 2625–2633. doi: 10.1093/eurheartj/ehn422Jacobson T.A., Ito M.K., Maki K.C., Orringer C.E., Bays H.E., Jones P.H., Brown W.V. National lipid association recommendations for patient-centered manage ment of dyslipidemia: part 1–full report. J. Clin. Lipidol., 2015; 9 (2): 129–169. doi: 10.1016/j.jacl.2015.02.003Jacobson T.A., Ito M.K., Maki K.C., Orringer C.E., Bays H.E., Jones P.H., Brown W.V. National lipid association recommendations for patient-centered manage ment of dyslipidemia: part 1–full report. J. Clin. Lipidol., 2015; 9 (2): 129–169. doi: 10.1016/j.jacl.2015.02.003Silva P.R., Jannes C.E., Marsiglia J.D., Krieger J.E., Santos R.D., Pereira A.C. Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia. Atherosclerosis, 2016; 250: 144–150. doi: 10.1016/j.atherosclerosis.2016.05.023Silva P.R., Jannes C.E., Marsiglia J.D., Krieger J.E., Santos R.D., Pereira A.C. Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia. Atherosclerosis, 2016; 250: 144–150. doi: 10.1016/j.atherosclerosis.2016.05.023Wu H., Forgetta V., Zhou S., Bhatnagar S.R., Paré G., Richards J.B. A Polygenic Risk Score for Low-density Lipoprotein Cholesterol is Associated with Risk of Ischemic Heart Disease and Enriches for Individuals with Familial Hypercholesterolemia. Circ. Genom. Precis. Med., 2020. doi: 10.1161/circgen.120.003106Wu H., Forgetta V., Zhou S., Bhatnagar S.R., Paré G., Richards J.B. A Polygenic Risk Score for Low-density Lipoprotein Cholesterol is Associated with Risk of Ischemic Heart Disease and Enriches for Individuals with Familial Hypercholesterolemia. Circ. Genom. Precis. Med., 2020. doi: 10.1161/circgen.120.003106Gidding S.S., Ann Champagne M., de Ferranti S.D., Defesche J., Ito M.K., Knowles J.W., Wierzbicki A.S. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation, 2015; 132 (22): 2167–2192. doi: 10.1161/cir.0000000000000297Gidding S.S., Ann Champagne M., de Ferranti S.D., Defesche J., Ito M.K., Knowles J.W., Wierzbicki A.S. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation, 2015; 132 (22): 2167–2192. doi: 10.1161/cir.0000000000000297Liu Z., Peng J., Wang S., Jiang T., Zhang W., Zhang C., Lin J. Percutaneous coronary intervention for a Chinese familial hypercholesterolemia homozygous under the guidance of optical coherence tomography. Atheroscler. Suppl., 2019; 36: 19–23. doi: 10.1016/j.atherosclerosissup.2019.01.004Liu Z., Peng J., Wang S., Jiang T., Zhang W., Zhang C., Lin J. Percutaneous coronary intervention for a Chinese familial hypercholesterolemia homozygous under the guidance of optical coherence tomography. Atheroscler. Suppl., 2019; 36: 19–23. doi: 10.1016/j.atherosclerosissup.2019.01.004Pang J., Abraham A., Vargas-García C., Bates T.R., Chan D.C., Hooper A.J., Watts G.F. An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia. Atherosclerosis, 2020; 298: 52–57. doi: 10.1016/j.atherosclerosis.2020.03.001Pang J., Abraham A., Vargas-García C., Bates T.R., Chan D.C., Hooper A.J., Watts G.F. An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia. Atherosclerosis, 2020; 298: 52–57. doi: 10.1016/j.atherosclerosis.2020.03.001Hashimoto T., Minami Y., Kakizaki R., Nemoto T., Fujiyoshi K., Meguro K., Ako J. Achilles tendon thickening is associated with disease severity and plaque vulnerability in patients with coronary artery disease. J. Clin. Lipidol., 2019; 13 (1): 194–200. doi: 10.1016/j.jacl.2018.10.007Hashimoto T., Minami Y., Kakizaki R., Nemoto T., Fujiyoshi K., Meguro K., Ako J. Achilles tendon thickening is associated with disease severity and plaque vulnerability in patients with coronary artery disease. J. Clin. Lipidol., 2019; 13 (1): 194–200. doi: 10.1016/j.jacl.2018.10.007Katamine M., Minami Y., Hashimoto T., Ako J. Familial hypercholesterolemia and vulnerability of coronary plaque in patients with coronary artery disease. Pract. Lab. Med., 2021; 24: 1–9. doi: 10.1016/j.plabm.2021.e00202Katamine M., Minami Y., Hashimoto T., Ako J. Familial hypercholesterolemia and vulnerability of coronary plaque in patients with coronary artery disease. Pract. Lab. Med., 2021; 24: 1–9. doi: 10.1016/j.plabm.2021.e00202Rubba P., Gentile M., Marotta G., Iannuzzi A., Sodano M., de Simone B., Fortunato G. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia. Eur. J. Prev. Cardiol., 2017; 24 (10): 1051–1059. doi: 10.1177/2047487317702040Rubba P., Gentile M., Marotta G., Iannuzzi A., Sodano M., de Simone B., Fortunato G. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia. Eur. J. Prev. Cardiol., 2017; 24 (10): 1051–1059. doi: 10.1177/2047487317702040Pérez de Isla L., Alonso R., Mata N., Saltijeral A., Muсiz O., Rubio-Marin P., Mata P. Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). Arterioscler. Thromb. Vasc. Biol., 2016; 36 (9): 2004–2010. doi: 10.1161/atvbana.116.307514Pérez de Isla L., Alonso R., Mata N., Saltijeral A., Muсiz O., Rubio-Marin P., Mata P. Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). Arterioscler. Thromb. Vasc. Biol., 2016; 36 (9): 2004–2010. doi: 10.1161/atvbana.116.307514Frikke-Schmidt R., Arlien-Søborg P., Thorsen S., Jensen H.K., Vorstrup S. LDL receptor mutations and ApoB mutations are not risk factors for ischemic cerebrovascular disease of the young, but lipids and lipoproteins are. Eur. J. Neurol., 1999; 6 (6): 691–696. doi: 10.1046/j.1468-1331.1999.660691.xFrikke-Schmidt R., Arlien-Søborg P., Thorsen S., Jensen H.K., Vorstrup S. LDL receptor mutations and ApoB mutations are not risk factors for ischemic cerebrovascular disease of the young, but lipids and lipoproteins are. Eur. J. Neurol., 1999; 6 (6): 691–696. doi: 10.1046/j.1468-1331.1999.660691.xHutter C.M., Melissa A.A., Steve E.H. Familial hypercholesterolemia, peripheral arterial disease, and stroke: a HuGE minireview. Am. J. Epidemiol., 2004; 160 (5): 430–435. doi: 10.1093/aje/kwh238Hutter C.M., Melissa A.A., Steve E.H. Familial hypercholesterolemia, peripheral arterial disease, and stroke: a HuGE minireview. Am. J. Epidemiol., 2004; 160 (5): 430–435. doi: 10.1093/aje/kwh238Huxley R.R., Hawkins M.H., Humphries S.E., Karpe F., Neil H.A. Risk of fatal stroke in patients with treated familial hypercholesterolemia: a prospective registry study. Stroke, 2003; 34 (1): 22–25. doi: 10.1161/01.str.0000047123.14312.3eHuxley R.R., Hawkins M.H., Humphries S.E., Karpe F., Neil H.A. Risk of fatal stroke in patients with treated familial hypercholesterolemia: a prospective registry study. Stroke, 2003; 34 (1): 22–25. doi: 10.1161/01.str.0000047123.14312.3eKaste M., Koivisto P. Risk of brain infarction in familial hypercholesterolemia. Stroke, 1988; 19 (9): 1097–1100. doi: 10.1161/01.str.19.9.1097Kaste M., Koivisto P. Risk of brain infarction in familial hypercholesterolemia. Stroke, 1988; 19 (9): 1097–1100. doi: 10.1161/01.str.19.9.1097Mabuchi H., Miyamoto S., Ueda K., Oota M., Takegoshi T., Wakasugi T., Takeda R. Causes of death in patients with familial hypercholesterolemia. Atherosclerosis, 1986; 61 (1): 1–6. doi: 10.1016/0021-9150(86)90107-3Mabuchi H., Miyamoto S., Ueda K., Oota M., Takegoshi T., Wakasugi T., Takeda R. Causes of death in patients with familial hypercholesterolemia. Atherosclerosis, 1986; 61 (1): 1–6. doi: 10.1016/0021-9150(86)90107-3Beheshti S., Madsen C.M., Varbo A., Benn M., Nordestgaard B.G. Relationship of familial hypercholesterolemia and high low-density lipoprotein cholesterol to ischemic stroke: Copenhagen general population study. Circulation, 2018; 138 (6): 578–589. doi: 10.1161/circulationaha.118.033470Beheshti S., Madsen C.M., Varbo A., Benn M., Nordestgaard B.G. Relationship of familial hypercholesterolemia and high low-density lipoprotein cholesterol to ischemic stroke: Copenhagen general population study. Circulation, 2018; 138 (6): 578–589. doi: 10.1161/circulationaha.118.033470Wang X., Cai G., Wang Y., Liu R., Xi Z., Li G., Zhou Y. Comparison of long-term outcomes of young patients after a coronary event associated with familial hypercholesterolemia. Lipids. Health. Dis., 2019; 18 (1): 1–7. doi: 10.1186/s12944-019-1074-8Wang X., Cai G., Wang Y., Liu R., Xi Z., Li G., Zhou Y. Comparison of long-term outcomes of young patients after a coronary event associated with familial hypercholesterolemia. Lipids. Health. Dis., 2019; 18 (1): 1–7. doi: 10.1186/s12944-019-1074-8Wu W.Y., Biery D.W., Singh A., Divakaran S., Berman A.N., Ayuba G., Blankstein R. Recovery of left ventricular systolic function and clinical outcomes in young adults with myocardial infarction. J. Am. Coll. Cardiol., 2020; 75 (22): 2804–2815. doi: 10.1016/j.jacc.2020.03.074Wu W.Y., Biery D.W., Singh A., Divakaran S., Berman A.N., Ayuba G., Blankstein R. Recovery of left ventricular systolic function and clinical outcomes in young adults with myocardial infarction. J. Am. Coll. Cardiol., 2020; 75 (22): 2804–2815. doi: 10.1016/j.jacc.2020.03.074Berman A.N., Biery D.W., Singh A., Wu W.Y., Divakaran S., DeFilippis E.M., Blankstein R. Atherosclerotic cardiovascular disease risk and elevated lipoprotein (a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. Eur. J. Prev. Cardiol., 2020; 1–4. 2047487320931296. doi: 10.1177/2047487320931296Berman A.N., Biery D.W., Singh A., Wu W.Y., Divakaran S., DeFilippis E.M., Blankstein R. Atherosclerotic cardiovascular disease risk and elevated lipoprotein (a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. Eur. J. Prev. Cardiol., 2020; 1–4. 2047487320931296. doi: 10.1177/2047487320931296Aggarwal A., Srivastava S., Velmurugan M. Newer perspectives of coronary artery disease in young. World. J. Cardiol., 2016; 8 (12): 728–734 doi: 10.4330/wjc.v8.i12.728Aggarwal A., Srivastava S., Velmurugan M. Newer perspectives of coronary artery disease in young. World. J. Cardiol., 2016; 8 (12): 728–734 doi: 10.4330/wjc.v8.i12.728Hatmi Z.N., Mahdavi-Mazdeh M., Hashemi-Nazari S.S., Hajighasemi E., Nozari B., Mahdavi A. Pattern of coronary artery disease risk factors in population younger than 55 years and above 55 years: a population study of 31999 healthy individuals. Acta. Med. Iran, 2011; 368–374. https://pubmed.ncbi.nlm.nih.gov/21874640/Hatmi Z.N., Mahdavi-Mazdeh M., Hashemi-Nazari S.S., Hajighasemi E., Nozari B., Mahdavi A. Pattern of coronary artery disease risk factors in population younger than 55 years and above 55 years: a population study of 31999 healthy individuals. Acta. Med. Iran, 2011; 368–374. https://pubmed.ncbi.nlm.nih.gov/21874640/Trinder M., Li X., DeCastro M.L., Cermakova L., Sadananda S., Jackson L.M., Brunham L.R. Risk of premature atherosclerotic disease in patients withmonogenic versus polygenic familial hypercholesterolemia. J. Am. Coll. Cardiol., 2019; 74 (4): 512–522. doi: 10.1016/j.jacc.2019.05.043Trinder M., Li X., DeCastro M.L., Cermakova L., Sadananda S., Jackson L.M., Brunham L.R. Risk of premature atherosclerotic disease in patients withmonogenic versus polygenic familial hypercholesterolemia. J. Am. Coll. Cardiol., 2019; 74 (4): 512–522. doi: 10.1016/j.jacc.2019.05.043Nordestgaard B.G., Benn M. Genetic testing for familial hypercholesterolaemia is essential in individuals with high LDL cholesterol: who does it in the world? Eur. Heart. J., 2017; 38: 1580–1583. doi: 10.1093/eurheartj/ehx136Nordestgaard B.G., Benn M. Genetic testing for familial hypercholesterolaemia is essential in individuals with high LDL cholesterol: who does it in the world? Eur. Heart. J., 2017; 38: 1580–1583. doi: 10.1093/eurheartj/ehx136Sturm A.C., Knowles J.W., Gidding S.S., Ahmad Z.S., Ahmed C.D., Ballantyne C.M. Clinical genetic testing for familial hypercholesterolemia JACC Scientific Expert Panel. J Am. Coll. Cardiol., 2018; 72: 662–680. doi: 10.1016/j.jacc.2018.05.04Sturm A.C., Knowles J.W., Gidding S.S., Ahmad Z.S., Ahmed C.D., Ballantyne C.M. Clinical genetic testing for familial hypercholesterolemia JACC Scientific Expert Panel. J Am. Coll. Cardiol., 2018; 72: 662–680. doi: 10.1016/j.jacc.2018.05.04Tada H., Kawashiri M.A., Nohara A., Inazu A., Mabuchi H., Yamagishi M. Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. Eur. Heart. J., 2017; 38: 1573–1579. doi: 10.1093/eurheartj/ehx004Tada H., Kawashiri M.A., Nohara A., Inazu A., Mabuchi H., Yamagishi M. Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. Eur. Heart. J., 2017; 38: 1573–1579. doi: 10.1093/eurheartj/ehx004Близнюк С.А., Бубнова М.Г., Ежов М.В. Семейная ГХС: современное состояние проблемы и лечебно-профилактическая помощь. Кардиоваскуляр. терапия и профилактика, 2020; 19 (5): 247–252. doi: 10.15829/1728-8800-2020-2532Bliznyuk S.A., Bubnova M.G., Ezhov M.V. Familial hypercholesterolemia: the current state of the problem and therapeutic and preventive care. Kardiovaskulyarnaya terapiya i profilaktika, 2020; 19 (5): 247–252. (In Russ.) doi: 10.15829/1728-8800-2020-2532Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease:consensus statement of the European Atherosclerosis Society. Eur. Heart. J., 2013; 34 (45): 3478–3490. doi: 10.1093/eurheartj/eht273Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease:consensus statement of the European Atherosclerosis Society. Eur. Heart. J., 2013; 34 (45): 3478–3490. doi: 10.1093/eurheartj/eht273Huijgen R., Hutten B.A., Kindt I., Vissers M.N., Kastelein J.J. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26 406 individuals tested for genetic FH. Circ. Cardiovasc. Genet., 2012; 5 (3): 354–359. doi: 10.1161/circgenetics.111.962456Huijgen R., Hutten B.A., Kindt I., Vissers M.N., Kastelein J.J. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26 406 individuals tested for genetic FH. Circ. Cardiovasc. Genet., 2012; 5 (3): 354–359. doi: 10.1161/circgenetics.111.962456Корнева В.А., Кузнецова Т.Ю., Тихова Г.П. Вариабельность уровней холестерина липопротеидов низкой плотности у пациентов с семейной гиперхолестеринемией в зависимости от возраста и пола и ее значение в диагностике данного заболевания. Рациональная фармакотерапия в кардиологии, 2017; 13 (1): 36–44. doi: 10.20996/1819-6446-2017-13-1-36-44Korneva V.A., Kuznetsova T.Yu., Tikhova G.P. Variability of low-density lipoprotein cholesterol levels in patients with familial hypercholesterolemia, depending on age and gender, and its significance in the diagnosis of this disease. Ratsional’naya farmakoterapiya v kardiologii, 2017; 13 (1): 36–44. (In Russ.) doi: 10.20996/1819-6446-2017-13-1-36-44Castaсer O., Pintу X., Subirana I., Amor A.J., Ros E., Hernáez Á., Fitу M. Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease. J. Am. Coll. Cardiol., 2020; 76 (23): 2712–2724. doi: 10.1016/j.jacc.2020.10.008Castaсer O., Pintу X., Subirana I., Amor A.J., Ros E., Hernáez Á., Fitу M. Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease. J. Am. Coll. Cardiol., 2020; 76 (23): 2712–2724. doi: 10.1016/j.jacc.2020.10.008Balling M., Afzal S., Varbo A., Langsted A., Davey Smith G., Nordestgaard B.G. VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins. J. Am. Coll. Cardiol., 2020; 76 (23): 2725–2735. doi: 10.1016/j.jacc.2020.09.610Balling M., Afzal S., Varbo A., Langsted A., Davey Smith G., Nordestgaard B.G. VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins. J. Am. Coll. Cardiol., 2020; 76 (23): 2725–2735. doi: 10.1016/j.jacc.2020.09.610Садыкова Д.И., Сусеков А.В., Леонтьева И.В., Закиров И.И., Сластникова Е.С., Галимова Л.Ф., Сабирова Д.Р., Криницкая Н.В. Нарушения липидного обмена и тиреотоксикоз. Рос. вестн. перинатологии и педиатрии, 2021; 65 (6): 91–97. doi: 10.21508/1027–4065–2020–65–6–91–97Sadykova D.I., Susekov A.V., Leont’eva I.V., Zakirov I.I., Slastnikova E.S., Galimova L.F., Sabirova D.R., Krinitskaya N.V. Disorders of lipid metabolism and thyrotoxicosis. Rossiiskii vestnik perinatologii i pediatrii, 2021; 65 (6): 91–97. (In Russ.) doi: 10.21508/1027–4065–2020–65–6–91–97Семакова А.Д., Брыкова Я.И. Оценка нарушения липидного обмена у больных с хронической болезнью почек. Молодежь, наука, медицина, 2018; 156–158. https://elibrary.ru/item.asp?id=37383687Semakova A.D., Brykova Ya.I. Assessment of lipid metabolism disorders in patients with chronic kidney disease. Molodezh’, Nauka, Meditsina, 2018; 156–158. (In Russ.) https://elibrary.ru/item.asp?id=37383687Zambon A. Холестерин, не связанный с липопротеинами высокой плотности, и сердечнососудистые заболевания у пациентов с сахарным диабетом и дислипидемией. Сахарный диабет, 2020; 23 (1): 65–71. doi: 10.14341/dm10351Zambon A. Non-high-density lipoprotein cholesterol and cardiovascular disease in patients with diabetic dyslipidaemia. Diabetes Mellitus, 2020; 23 (1): 65–71. (In Russ.) doi: 10.14341/dm10351Овсянникова А.К., Щербакова Л.В., Мустафина С.В., Рагино Ю.И., Денисова Д.В., Кунцевич А.К., Рымар О.Д. Показатели липидного профиля у лиц молодого возраста с впервые выявленным сахарным диабетом 2 типа. Атеросклероз, 2018; 14 (3): 39–44. doi: 10.15372/ater20180306Ovsyannikova A.K., Shcherbakova L.V., Mustafina S.V., Ragino Yu.I., Denisova D.V., Kuntsevich A.K., Rymar O.D. Lipid profile indicators in young people with newly diagnosed type 2 diabetes mellitus. Ateroskleroz, 2018; 14 (3): 39–44. (In Russ.) doi: 10.15372/ater20180306Akioyamen L.E., Genest J., Chu A., Inibhunu H., Ko D.T., Tu J.V. Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. J. Clin. Lipidol., 2019; 13 (1): 15–30. doi: 10.1016/j.jacl.2018.10.012.Akioyamen L.E., Genest J., Chu A., Inibhunu H., Ko D.T., Tu J.V. Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. J. Clin. Lipidol., 2019; 13 (1): 15–30. doi: 10.1016/j.jacl.2018.10.012.Naghavi M., Falk E., Hecht H.S., Jamieson M.J., Kaul S., Berman D., Shah P.K. alSHAPE Task Force. From vulnerable plaque to vulnerable patient e part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am. J. Cardiol., 2006; 98: 2–15 doi: 10.1016/j.amjcard.2006.03.002Naghavi M., Falk E., Hecht H.S., Jamieson M.J., Kaul S., Berman D., Shah P.K. alSHAPE Task Force. From vulnerable plaque to vulnerable patient e part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am. J. Cardiol., 2006; 98: 2–15 doi: 10.1016/j.amjcard.2006.03.002Pérez de Isla L., Alonso R., Mata N. Predicting Cardiovascular Events in Familial Hypercholesterolemia: The safeheart Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation, 2017; 135 (11): 2133–2144. doi: 10.1161/circulationaha.116.024541.Pérez de Isla L., Alonso R., Mata N. Predicting Cardiovascular Events in Familial Hypercholesterolemia: The safeheart Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation, 2017; 135 (11): 2133–2144. doi: 10.1161/circulationaha.116.024541.Raiko J., Magnussen C.G., Kivimäki M., Taittonen L., Laitinen T., Kähönen M., Juonala M. Cardiovascular risk scores in the prediction of subclinical atherosclerosis in young adults: evidence from the cardiovascular risk in a young Finns study. Eur. J. Prev. Cardiol., 2010; 17 (5): 549–555. doi: 10.1097/hjr.0b013e3283386419Raiko J., Magnussen C.G., Kivimäki M., Taittonen L., Laitinen T., Kähönen M., Juonala M. Cardiovascular risk scores in the prediction of subclinical atherosclerosis in young adults: evidence from the cardiovascular risk in a young Finns study. Eur. J. Prev. Cardiol., 2010; 17 (5): 549–555. doi: 10.1097/hjr.0b013e3283386419Kuller L.H. Prevention of coronary heart disease and the National Cholesterol Education Program. Circulation, 2006; 113: 598–560. doi: 10.1161/circulationaha.105.604595Kuller L.H. Prevention of coronary heart disease and the National Cholesterol Education Program. Circulation, 2006; 113: 598–560. doi: 10.1161/circulationaha.105.604595Bhopal R., Fischbacher C., Vartiainen E., Unwin N., White M., Alberti G. Predicted and observed cardiovascular disease in South Asians: application of finrisk, Framingham and SCORE models to Newcastle Heart Project data. J. Public. Health., 2005; 27 (1): 93–100. doi: 10.1093/pubmed/fdh202Bhopal R., Fischbacher C., Vartiainen E., Unwin N., White M., Alberti G. Predicted and observed cardiovascular disease in South Asians: application of finrisk, Framingham and SCORE models to Newcastle Heart Project data. J. Public. Health., 2005; 27 (1): 93–100. doi: 10.1093/pubmed/fdh202Ridker P.M., Paynter N.P., Rifai N., Gaziano J.M., Cook N.R. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation, 2008; 118 (22): 2243–2251. doi: 10.1161/circulationaha.108.814251Ridker P.M., Paynter N.P., Rifai N., Gaziano J.M., Cook N.R. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation, 2008; 118 (22): 2243–2251. doi: 10.1161/circulationaha.108.814251Ridker P.M., Buring J.E., Rifai N., Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. Jama, 2007; 297 (6): 611–619. doi: 10.1001/jama.297.6.611Ridker P.M., Buring J.E., Rifai N., Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. Jama, 2007; 297 (6): 611–619. doi: 10.1001/jama.297.6.611Ketola E., Laatikainen T., Vartiainen E. Evaluating risk for cardiovascular diseases–vain or value? How do different cardiovascular risk scores act in real life. J. Public. Health., 2010; 20 (1): 107–112. doi: 10.1093/eurpub/ckp070Ketola E., Laatikainen T., Vartiainen E. Evaluating risk for cardiovascular diseases–vain or value? How do different cardiovascular risk scores act in real life. J. Public. Health., 2010; 20 (1): 107–112. doi: 10.1093/eurpub/ckp070McMahan C.A., Gidding S.S., Fayad Z.A., Zieske A.W., Malcom G.T., Tracy R.E., McGill H.C. Risk scores predict atherosclerotic lesions in young people. Arch. Intern. Med., 2005; 165 (8): 883–890. doi: 10.1001/archinte.165.8.883McMahan C.A., Gidding S.S., Fayad Z.A., Zieske A.W., Malcom G.T., Tracy R.E., McGill H.C. Risk scores predict atherosclerotic lesions in young people. Arch. Intern. Med., 2005; 165 (8): 883–890. doi: 10.1001/archinte.165.8.883McCrindle B.W. Familial hypercholesterolemia in children and adolescents. Curr. Opin. Lipidol., 2012; 23 (6): 525–531. doi: 10.1097/mol.0b013e3283587522McCrindle B.W. Familial hypercholesterolemia in children and adolescents. Curr. Opin. Lipidol., 2012; 23 (6): 525–531. doi: 10.1097/mol.0b013e3283587522Ячменева М.П., Рагино Ю.И. Роль гиперлипидемии и гипергликемии в развитии ишемической болезни сердца в молодой популяции. Атеросклероз, 2018; 14 (1): 38–42. doi: 10.15372/ater20180105Yachmeneva M.P., Ragino Yu.I. The role of hyperlipidemia and hyperglycemia in the development of coronary heart disease in a young population. Ateroskleroz, 2018; 14 (1): 38–42. (In Russ.) doi: 10.15372/ater20180105Goldstein J.L., Brown M.S. The LDL receptor. Arterioscler. Thromb. Vasc. Biol., 2009; 29 (4): 431–438. doi: 10.1161/atvbaha.108.179564Goldstein J.L., Brown M.S. The LDL receptor. Arterioscler. Thromb. Vasc. Biol., 2009; 29 (4): 431–438. doi: 10.1161/atvbaha.108.179564Ference B., Yoo W., Ales I., Mahajan N., Mirowska K.K., Mewada A. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J. Am. Coll. Cardiol., 2012; 60 (25): 2631–2639. doi: 10.1016/j.jacc.2012.09.017Ference B., Yoo W., Ales I., Mahajan N., Mirowska K.K., Mewada A. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J. Am. Coll. Cardiol., 2012; 60 (25): 2631–2639. doi: 10.1016/j.jacc.2012.09.017Real J.T., Chaves F.J., Martinez-Uso I., GarcíaGarcía A.B., Ascaso J.F., Carmena R. Importance of HDL cholesterol levels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia. Eur. Heart. J., 2001; 22 (6): 465–471. doi: org/10.1053/euhj.2000.2408Real J.T., Chaves F.J., Martinez-Uso I., GarcíaGarcía A.B., Ascaso J.F., Carmena R. Importance of HDL cholesterol levels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia. Eur. Heart. J., 2001; 22 (6): 465–471. doi: org/10.1053/euhj.2000.2408Хрипунова А.А., Боева О.И., Джанибекова А.Р., Краснов А.Ю., Хрипунова И.Г. Эпидемиология и особенности диагностики семейной ГХС в российской популяции. Терапия, 2020; 6 (5): 147–156. doi: 10.18565/therapy.2020.5.147–156Khripunova A.A., Boeva O.I., Dzhanibekova A.R., Krasnov A.Yu., Khripunova I.G. Epidemiology and diagnostic features of familial hypercholesterolemia in the Russian population. Terapiya, 2020; 6 (5): 147–156. (In Russ.) doi: 10.18565/therapy.2020.5.147–156Чубыкина У.В., Афанасьева О.И., Тмоян Н.А., Ежов М.В. Программы наблюдения и скрининга больных с семейной гиперхолестеринемией. Атеросклероз и дислипидемии, 2020; 11 (2): 43–48. doi: 10.34687/2219–8202.jad.2020.02.0006Chubykina U.V., Afanas’eva O.I., Tmoyan N.A., Ezhov M.V. Monitoring and screening programs for patients with familial hypercholesterolemia. Ateroskleroz i dislipidemii, 2020; 11 (2): 43–48. (In Russ.) doi: 10.34687/2219–8202.jad.2020.02.0006Allard M.D., Saeedi R., Yousefi M., Frohlich J. Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort. Lipids. Health. Dis., 2014; 13 (1): 1–7. doi: 10.1186/1476-511X-13-65Allard M.D., Saeedi R., Yousefi M., Frohlich J. Risk stratification of patients with familial hypercholesterolemia in a multi-ethnic cohort. Lipids. Health. Dis., 2014; 13 (1): 1–7. doi: 10.1186/1476-511X-13-65Al-Rasadi K., Al-Waili K., Al-Sabti H.A., Al-Hinai A., Al-Hashmi K., Al-Zakwani I., Banerjee Y. Criteria for diagnosis of familial hypercholesterolemia: a comprehensive analysis of the different guidelines, appraising their suitability in the Omani Arab population. Oman. Med. J., 2014; 29 (2): 85–91. doi: 10.5001/omj.2014.22Al-Rasadi K., Al-Waili K., Al-Sabti H.A., Al-Hinai A., Al-Hashmi K., Al-Zakwani I., Banerjee Y. Criteria for diagnosis of familial hypercholesterolemia: a comprehensive analysis of the different guidelines, appraising their suitability in the Omani Arab population. Oman. Med. J., 2014; 29 (2): 85–91. doi: 10.5001/omj.2014.22Суворова Н.Н. Методы выявления и оценка риска осложнений при наследственно-обусловленных нарушениях липидного обмена во врачебной практике. Обзор литературы. Кремлевская медицина. Клинический вестник, 2018; 4: 87–91. https://www.elibrary.ru/item.asp?id=36716940Suvorova N.N. Methods for identifying and assessing the risk of complications in hereditary disorders of lipid metabolism in medical practice. Literature review. Kremlevskaya meditsina. Klinicheskii vestnik, 2018; 4: 87–91. (In Russ.) https://www.elibrary.ru/item.asp?id=36716940Ahmad Z.S., Andersen R.L., Andersen L.H., O’Brien E.C., Kindt I., Shrader P., Knowles J.W. US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. J. Clin. Lipidol., 2016; 10 (5): 1223–1229. doi: 10.1016/j.jacl.2016.07.011Ahmad Z.S., Andersen R.L., Andersen L.H., O’Brien E.C., Kindt I., Shrader P., Knowles J.W. US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. J. Clin. Lipidol., 2016; 10 (5): 1223–1229. doi: 10.1016/j.jacl.2016.07.011Gidding S.S., Sheldon A., Neben C.L., Williams H.E., Law S., Zhou A.Y., Kindt I. Patient acceptance of genetic testing for familial hypercholesterolemia in the cascade FH registry. J. Clin. Lipidol., 2020; 14 (2): 218–223. doi: 10.1016/j.jacl.2020.02.001Gidding S.S., Sheldon A., Neben C.L., Williams H.E., Law S., Zhou A.Y., Kindt I. Patient acceptance of genetic testing for familial hypercholesterolemia in the cascade FH registry. J. Clin. Lipidol., 2020; 14 (2): 218–223. doi: 10.1016/j.jacl.2020.02.001Галимова Л.Ф., Садыкова Д.И., Сластникова Е.С., Усова Н.Э. Диагностика семейной ГХС у детей: каскадный скрининг от теории к практике. Кардиоваскуляр. терапия и профилактика, 2020; 19 (3): 191–196. doi: 10.15829/1728- 8800-2020-2348Galimova L.F., Sadykova D.I., Slastnikova E.S., Usova N.Eh. Diagnosis of familial hypercholesterolemia in children: cascade screening from theory to practice. Kardiovaskulyarnaya terapiya i profilaktika, 2020; 19 (3): 191–196. (In Russ.) doi: 10.15829/1728- 8800-2020-2348Ежов М.В. и др. Регистр пациентов с семейной гиперхолестеринемией и пациентов очень высокого сердечно-сосудистого риска с недостаточной эффективностью проводимой гиполипидемической терапии (РЕНЕССАНС). Рос. кардиол. журн., 2019: 24 (5); 7–13. doi: 10.15829/1560-4071-2019-5-7-13Yezhov M.V., Bliznyuk S.A., Tmoyan N.A., Rozhkova T.A., Duplyakov D.V., Salchenko V.A., Voyevoda M.I. Register of patients with familial hypercholesterolemia and patients of very high cardiovascular risk with lipid-lowering therapy underperformance (renessans). Russian Journal of Cardiology, 2019; (5): 7–13. (In Russ.) doi: 10.15829/1560-4071-2019-5-7-13Si J., Li J., Yu C., Guo Y., Bian Z., Millwood I., Lv J. Improved lipidomic profile mediates the effects of adherence to healthy lifestyles on coronary heart disease. Elife, 2021; 10: 1–16. doi: 10.7554/eLife.60999Si J., Li J., Yu C., Guo Y., Bian Z., Millwood I., Lv J. Improved lipidomic profile mediates the effects of adherence to healthy lifestyles on coronary heart disease. Elife, 2021; 10: 1–16. doi: 10.7554/eLife.60999Hu P., Dharmayat K.I., Stevens C.A., Sharabiani M.T., Jones R.S., Watts G.F., Vallejo-Vaz A.J. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and metaanalysis. Circulation, 2020; 141 (22): 1742–1759. doi: 10.1161/circulationaha.119.044795Hu P., Dharmayat K.I., Stevens C.A., Sharabiani M.T., Jones R.S., Watts G.F., Vallejo-Vaz A.J. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and metaanalysis. Circulation, 2020; 141 (22): 1742–1759. doi: 10.1161/circulationaha.119.044795Singh A., Gupta A., Collins B.L., Qamar A., Monda K.L., Biery D., Blankstein R. Familial hypercholesterolemia among young adults with myocardial infarction. J. Am. Coll. Cardiol., 2019; 73 (19): 2439–2450. doi: 10.1016/j.jacc.2019.02.059Singh A., Gupta A., Collins B.L., Qamar A., Monda K.L., Biery D., Blankstein R. Familial hypercholesterolemia among young adults with myocardial infarction. J. Am. Coll. Cardiol., 2019; 73 (19): 2439–2450. doi: 10.1016/j.jacc.2019.02.059Langslet G., Bogsrud M.P., Halvorsen I., Fjeldstad H., Retterstøl K., Veierød M.B., Ose L. Long-term followup of young adults with familial hypercholesterolemia after participation in clinical trials during childhood. J. Clin. Lipidol., 2015; 9 (6): 778–785. doi: 10.1016/j.jacl.2015.08.008Langslet G., Bogsrud M.P., Halvorsen I., Fjeldstad H., Retterstøl K., Veierød M.B., Ose L. Long-term followup of young adults with familial hypercholesterolemia after participation in clinical trials during childhood. J. Clin. Lipidol., 2015; 9 (6): 778–785. doi: 10.1016/j.jacl.2015.08.008Brunham L.R., Ruel I., Aljenedil S., Rivière J.B., Baass A., Tu J.V., Brophy J. Canadian Cardiovascular Society position statement on familial hypercholesterolemia: update 2018. Can. J. Cardiol., 2018; 34 (12): 1553–1563. doi: 10.1016/j.cjca.2018.09.005Brunham L.R., Ruel I., Aljenedil S., Rivière J.B., Baass A., Tu J.V., Brophy J. Canadian Cardiovascular Society position statement on familial hypercholesterolemia: update 2018. Can. J. Cardiol., 2018; 34 (12): 1553–1563. doi: 10.1016/j.cjca.2018.09.005McKay A.J., Hogan H., Humphries S.E., Marks D., Ray K.K., Miners A. Universal screening at age 1–2 years as an adjunct to cascade testing for famili al hypercholesterolaemia in the UK: a cost-utility analysis. Atherosclerosis, 2018; 275: 434–443. doi: 10.1016/j.atherosclerosis.2018.05.047McKay A.J., Hogan H., Humphries S.E., Marks D., Ray K.K., Miners A. Universal screening at age 1–2 years as an adjunct to cascade testing for famili al hypercholesterolaemia in the UK: a cost-utility analysis. Atherosclerosis, 2018; 275: 434–443. doi: 10.1016/j.atherosclerosis.2018.05.047Watts G.F., Gidding S.S., Mata P., Pang J., Sullivan D.R., Yamashita S., Ray K.K. Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nat. Rev. Cardiol., 2020; 17 (6): 360–377. doi: 10.1038/s41569-019-0325-8Watts G.F., Gidding S.S., Mata P., Pang J., Sullivan D.R., Yamashita S., Ray K.K. Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nat. Rev. Cardiol., 2020; 17 (6): 360–377. doi: 10.1038/s41569-019-0325-8Dombalis S., Nash A. The Effect of Statins in Children and Adolescents With Familial Hypercholesterolemia: A Systematic Review. J. Pediatr. Health. Care., 2020. doi: 10.1016/j.pedhc.2020.11.007Dombalis S., Nash A. The Effect of Statins in Children and Adolescents With Familial Hypercholesterolemia: A Systematic Review. J. Pediatr. Health. Care., 2020. doi: 10.1016/j.pedhc.2020.11.007Daniels S., Caprio S., Chaudhari U., Manvelian G., Baccara-Dinet M.T., Brunet A., Bruckert E. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The odyssey kids study. J. Clinical. Lipidol., 2020; 14 (3): 322–330. doi: 10.1016/j.jacl.2020.03.001Daniels S., Caprio S., Chaudhari U., Manvelian G., Baccara-Dinet M.T., Brunet A., Bruckert E. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The odyssey kids study. J. Clinical. Lipidol., 2020; 14 (3): 322–330. doi: 10.1016/j.jacl.2020.03.001Gaudet D., Langslet G., Gidding S.S., Luirink I.K., Ruzza A., Kurtz C., Wiegman A. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: rationale and design of the HAUSER-RCT study. J. Clinical. Lipidol., 2018; 12 (5): 1199–1207. doi: 10.1016/j.jacl.2018.05.007Gaudet D., Langslet G., Gidding S.S., Luirink I.K., Ruzza A., Kurtz C., Wiegman A. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: rationale and design of the HAUSER-RCT study. J. Clinical. Lipidol., 2018; 12 (5): 1199–1207. doi: 10.1016/j.jacl.2018.05.007Santos R.D., Ruzza A., Hovingh G.K., Wiegman A., Mach F., Kurtz C.E., Gaudet D. Evolocumab in pediatric heterozygous familial hypercholesterolemia. N. Engl. J. Med., 2020; 383 (14): 1317–1327. doi: 10.1056/nejmoa2019910Santos R.D., Ruzza A., Hovingh G.K., Wiegman A., Mach F., Kurtz C.E., Gaudet D. Evolocumab in pediatric heterozygous familial hypercholesterolemia. N. Engl. J. Med., 2020; 383 (14): 1317–1327. doi: 10.1056/nejmoa2019910Frangoul H., Altshuler D., Cappellini M.D., Chen Y.S., Domm J., Eustace B.K., Corbacioglu S. Crispr-Cas9 gene editing for sickle cell disease and β-thalassemia. N. Engl. J. Med., 2021; 384 (3): 252–260. doi: 10.1056/nejmoa2031054Frangoul H., Altshuler D., Cappellini M.D., Chen Y.S., Domm J., Eustace B.K., Corbacioglu S. Crispr-Cas9 gene editing for sickle cell disease and β-thalassemia. N. Engl. J. Med., 2021; 384 (3): 252–260. doi: 10.1056/nejmoa2031054Zhao H. In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia. Circulation, 2020; 141 (1): 67–79. doi: 10.1161/circulationaha.119.042476Zhao H. In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia. Circulation, 2020; 141 (1): 67–79. doi: 10.1161/circulationaha.119.042476Gupta D., Bhattacharjee O., Mandal D., Sen M.K., Dey D., Dasgupta A., Ghosh D. CRISPR-Cas9 system: A new-fangled dawn in gene editing. Life. Sci., 2019; 232: 15–18. doi: 10.1016/j.lfs.2019.116636Gupta D., Bhattacharjee O., Mandal D., Sen M.K., Dey D., Dasgupta A., Ghosh D. CRISPR-Cas9 system: A new-fangled dawn in gene editing. Life. Sci., 2019; 232: 15–18. doi: 10.1016/j.lfs.2019.116636Li Y., Teng X., Zhang K., Deng R., Li J. RNA strand displacement responsive CRISPR/Cas9 system for mRNA sensing. Anal. Chem., 2019; 91 (6): 3989–3996. doi: 10.1021/acs.analchem.8b05238Li Y., Teng X., Zhang K., Deng R., Li J. RNA strand displacement responsive CRISPR/Cas9 system for mRNA sensing. Anal. Chem., 2019; 91 (6): 3989–3996. doi: 10.1021/acs.analchem.8b05238Borges J.B. Genomics, epigenomics and pharmacogenomics of Familial Hypercholesterolemia (FHBGEP): A study protocol. Res. Social. Adm. Pharm., 2021; 17 (7): 1347–1355. doi: 10.1016/j.sapharm.2020.10.007Borges J.B. Genomics, epigenomics and pharmacogenomics of Familial Hypercholesterolemia (FHBGEP): A study protocol. Res. Social. Adm. Pharm., 2021; 17 (7): 1347–1355. doi: 10.1016/j.sapharm.2020.10.007Камалова А.А. Диета при гиперхолестеринемии у детей. Вопр. соврем. педиатрии, 2020; 19 (4): 309–315. doi: 10.15690/vsp.v19i4.2140Kamalova A.A. Diet for hypercholesterolemia in children. Questions of modern pediatrics. Voprosy sovremennoi pediatrii, 2020; 19 (4): 309–315. (In Russ.) doi: 10.15690/vsp.v19i4.2140Khera A.V. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N. Engl. J. Med., 2016; 375 (24): 2349–2358. doi: 10.1056/nejmoa1605086Khera A.V. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N. Engl. J. Med., 2016; 375 (24): 2349–2358. doi: 10.1056/nejmoa1605086Defesche J.C., Gidding S.S., Harada-Shiba M., Hegele R.A., Santos R.D., Wierzbicki A.S. Familial hypercholesterolaemia. Nat. Rev. Dis. Primers., 2017; 3 (1): 1–20. doi: 10.1038/nrdp.2017.93Defesche J.C., Gidding S.S., Harada-Shiba M., Hegele R.A., Santos R.D., Wierzbicki A.S. Familial hypercholesterolaemia. Nat. Rev. Dis. Primers., 2017; 3 (1): 1–20. doi: 10.1038/nrdp.2017.93Stein E.A., Dann E.J., Wiegman A., Skovby F., Gaudet D., Sokal E., Kastelein J.J. Efficacy of rosuvastatin in children with homozygous familial hypercholesterolemia and association with underlying genetic mutations. J. Am. Coll. Cardiol., 2017; 70 (9): 1162–1170. doi: 10.1016/j.jacc.2017.06.058Stein E.A., Dann E.J., Wiegman A., Skovby F., Gaudet D., Sokal E., Kastelein J.J. Efficacy of rosuvastatin in children with homozygous familial hypercholesterolemia and association with underlying genetic mutations. J. Am. Coll. Cardiol., 2017; 70 (9): 1162–1170. doi: 10.1016/j.jacc.2017.06.058Bourbon M., Alves A.C., Alonso R., Mata N., Aguiar P., Padrу T., Mata P. Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry. Atherosclerosis, 2017; 262: 8–13. doi: 10.1016/j.atherosclerosis.2017.04.002Bourbon M., Alves A.C., Alonso R., Mata N., Aguiar P., Padrу T., Mata P. Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry. Atherosclerosis, 2017; 262: 8–13. doi: 10.1016/j.atherosclerosis.2017.04.002Леонтьева И.В. Современная стратегия диагностики и лечения семейной гетерозиготной ГХС у детей. Рос. вестн. перинатологии и педиатрии, 2020; 65 (4): 27–40. doi: 10.21508/1027-4065-2020-65-4-27-40Leont’eva I.V. Modern strategy for the diagnosis and treatment of familial heterozygous hypercholesterolemia in children. Rossiyskii vestnik perinatologii i pediatrii, 2020; 65 (4): 27–40. (In Russ.) doi: 10.21508/1027-4065-2020-65-4-27-40Ellis K.L., Pang J., Schultz C.J., Watts G.F. New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials. Eur. J. Prev. Cardiol., 2017; 24 (11): 1200–1205. doi: 10.1177/2047487317708890Ellis K.L., Pang J., Schultz C.J., Watts G.F. New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials. Eur. J. Prev. Cardiol., 2017; 24 (11): 1200–1205. doi: 10.1177/2047487317708890

The authors declare that there are no conflicts of interest present.